{ "version": "2.2", "instance": { "astrazeneca_i11k.htm": { "nsprefix": "AZN", "nsuri": "http://astrazeneca.com/20251231", "dts": { "inline": { "local": [ "astrazeneca_i11k.htm" ] }, "schema": { "local": [ "azn-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/ebp/elts/us-gaap-ebp-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "azn-20251231_cal.xml" ] }, "definitionLink": { "local": [ "azn-20251231_def.xml" ] }, "labelLink": { "local": [ "azn-20251231_lab.xml" ] }, "presentationLink": { "local": [ "azn-20251231_pre.xml" ] } }, "keyStandard": 69, "keyCustom": 7, "axisStandard": 5, "axisCustom": 0, "memberStandard": 12, "memberCustom": 6, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 125, "entityCount": 1, "segmentCount": 18, "elementCount": 206, "unitCount": 3, "baseTaxonomies": { "http://fasb.org/us-gaap-ebp/2025": 210, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://astrazeneca.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R2": { "role": "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits", "longName": "00000002 - Statement - Statements of Net Assets Available for Benefits", "shortName": "Statements of Net Assets Available for Benefits", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairAndContractValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R3": { "role": "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits", "longName": "00000003 - Statement - Statement of Changes in Net Assets Available for Benefits", "shortName": "Statement of Changes in Net Assets Available for Benefits", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForGainLossOnInvestment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForInterestAndDividendIncomeOnInvestment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R4": { "role": "http://astrazeneca.com/role/DescriptionOfPlan", "longName": "999004 - Disclosure - Description of Plan", "shortName": "Description of Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "4", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R5": { "role": "http://astrazeneca.com/role/SignificantAccountingPolicies", "longName": "999005 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "5", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanSummaryOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanSummaryOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R6": { "role": "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts", "longName": "999006 - Disclosure - Fully Benefit-Responsive Investment Contracts", "shortName": "Fully Benefit-Responsive Investment Contracts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R7": { "role": "http://astrazeneca.com/role/FairValueMeasurements", "longName": "999007 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R8": { "role": "http://astrazeneca.com/role/InternalRevenueServiceStatus", "longName": "999008 - Disclosure - Internal Revenue Service Status", "shortName": "Internal Revenue Service Status", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanTaxStatusTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanTaxStatusTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R9": { "role": "http://astrazeneca.com/role/PlanTermination", "longName": "999009 - Disclosure - Plan Termination", "shortName": "Plan Termination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanPlanTerminationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanPlanTerminationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R10": { "role": "http://astrazeneca.com/role/Party-in-interestTransactions", "longName": "999010 - Disclosure - Party-in-Interest Transactions", "shortName": "Party-in-Interest Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R11": { "role": "http://astrazeneca.com/role/RisksAndUncertainties", "longName": "999011 - Disclosure - Risks and Uncertainties", "shortName": "Risks and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanRiskAndUncertaintyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanRiskAndUncertaintyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R12": { "role": "http://astrazeneca.com/role/PlanAmendments", "longName": "999012 - Disclosure - Plan Amendments", "shortName": "Plan Amendments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanAmendmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanAmendmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R13": { "role": "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500", "longName": "999013 - Disclosure - Reconciliation of Financial Statements to Form 5500", "shortName": "Reconciliation of Financial Statements to Form 5500", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R14": { "role": "http://astrazeneca.com/role/PlanAssetsTransferred", "longName": "999014 - Disclosure - Plan Assets Transferred", "shortName": "Plan Assets Transferred", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "AZN:EBPPlanAssetsTransferredInTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "AZN:EBPPlanAssetsTransferredInTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R15": { "role": "http://astrazeneca.com/role/SubsequentEvents", "longName": "999015 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanSubsequentEventTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanSubsequentEventTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R16": { "role": "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear", "longName": "999016 - Disclosure - Schedule of Assets (Held at End of Year)", "shortName": "Schedule of Assets (Held at End of Year)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R17": { "role": "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies", "longName": "999017 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanBasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanSummaryOfAccountingPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanBasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanSummaryOfAccountingPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R18": { "role": "http://astrazeneca.com/role/DescriptionOfPlanTables", "longName": "999018 - Disclosure - Description of Plan (Tables)", "shortName": "Description of Plan (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanContributionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanContributionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R19": { "role": "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables", "longName": "999019 - Disclosure - Fully Benefit-Responsive Investment Contracts (Tables)", "shortName": "Fully Benefit-Responsive Investment Contracts (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R20": { "role": "http://astrazeneca.com/role/FairValueMeasurementsTables", "longName": "999020 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R21": { "role": "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables", "longName": "999021 - Disclosure - Reconciliation of Financial Statements to Form 5500 (Tables)", "shortName": "Reconciliation of Financial Statements to Form 5500 (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP001Member", "name": "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP001Member", "name": "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R22": { "role": "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions", "longName": "999022 - Disclosure - Description of Plan (Details - Contributions)", "shortName": "Description of Plan (Details - Contributions)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "AZN:EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheOne", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap-ebp:EmployeeBenefitPlanContributionTableTextBlock", "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "AZN:EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheOne", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap-ebp:EmployeeBenefitPlanContributionTableTextBlock", "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R23": { "role": "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "longName": "999023 - Disclosure - Description of Plan (Details Narrative)", "shortName": "Description of Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanParticipantContributionPretaxMaximumAnnualCompensationToTotalCompensationPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanParticipantContributionPretaxMaximumAnnualCompensationToTotalCompensationPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap-ebp:EmployeeBenefitPlanDescriptionOfPlanTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true, "unique": true } }, "R24": { "role": "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "longName": "999024 - Disclosure - Fully Benefit-Responsive Investment Contracts (Details - Investment contracts)", "shortName": "Fully Benefit-Responsive Investment Contracts (Details - Investment contracts)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustContractValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member_us-gaap-ebp_EmployeeBenefitPlanTraditionalGuaranteedInvestmentContractMember", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustContractValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTableTextBlock", "us-gaap-ebp:EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R25": { "role": "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "longName": "999025 - Disclosure - Fair Value Measurements (Details - Fair values of investment)", "shortName": "Fair Value Measurements (Details - Fair values of investment)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member_us-gaap_FairValueInputsLevel12And3Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentPlanInterestInMasterTrustFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTableTextBlock", "us-gaap-ebp:EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R26": { "role": "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative", "longName": "999026 - Disclosure - Party-in-Interest Transactions (Details Narrative)", "shortName": "Party-in-Interest Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForGainLossOnInvestment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member_custom_EBPAZCommonStockMember", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentAcquiredExcludingPlanInterestInMasterTrustCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap-ebp:EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R27": { "role": "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "longName": "999027 - Disclosure - Reconciliation of Financial Statements to Form 5500 (Details - Reconciliation)", "shortName": "Reconciliation of Financial Statements to Form 5500 (Details - Reconciliation)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanNetAssetAvailableForBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500NetAssetAvailableForBenefitContractValueToCurrentValueAdjustment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TableTextBlock", "us-gaap-ebp:EmployeeBenefitPlanReconciliationToForm5500TextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R28": { "role": "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative", "longName": "999028 - Disclosure - Plan Assets Transferred (Details Narrative)", "shortName": "Plan Assets Transferred (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitTransferToFromExternalPlan", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitTransferToFromFundWithinEsop", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "AZN:EBPPlanAssetsTransferredInTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } }, "R29": { "role": "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails", "longName": "999029 - Disclosure - Schedule of Assets (Held at End of Year) (Details)", "shortName": "Schedule of Assets (Held at End of Year) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_EBP002Member", "name": "us-gaap-ebp:EmployeeBenefitPlanAssetHeldForInvestmentParticipantLoanAfterDeemedDistribution", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap-ebp:EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "astrazeneca_i11k.htm", "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r156" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r156" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "AZN_DisclosureLineitem": { "xbrltype": "stringItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "DisclosureLineitem", "presentation": [ "http://astrazeneca.com/role/PlanAssetsTransferred", "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "DisclosureLineitem [Line Items]" } } }, "auth_ref": [] }, "AZN_DisclosurePlanAssetsTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "DisclosurePlanAssetsTransferredAbstract", "auth_ref": [] }, "AZN_DisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "DisclosureTable", "presentation": [ "http://astrazeneca.com/role/PlanAssetsTransferred", "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "DisclosureTable [Table]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r155" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r153", "r155", "r156" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r154" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r142" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r155" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r155" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r157" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r145" ] }, "AZN_EBP001Member": { "xbrltype": "domainItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBP001Member", "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables" ], "lang": { "en-us": { "role": { "label": "E B P 001 [Member]" } } }, "auth_ref": [] }, "AZN_EBP002Member": { "xbrltype": "domainItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBP002Member", "presentation": [ "http://astrazeneca.com/role/Cover", "http://astrazeneca.com/role/DescriptionOfPlan", "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions", "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/DescriptionOfPlanTables", "http://astrazeneca.com/role/FairValueMeasurements", "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FairValueMeasurementsTables", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables", "http://astrazeneca.com/role/InternalRevenueServiceStatus", "http://astrazeneca.com/role/Party-in-interestTransactions", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative", "http://astrazeneca.com/role/PlanAmendments", "http://astrazeneca.com/role/PlanAssetsTransferred", "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative", "http://astrazeneca.com/role/PlanTermination", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "http://astrazeneca.com/role/RisksAndUncertainties", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails", "http://astrazeneca.com/role/SignificantAccountingPolicies", "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies", "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "EBP 002 [Member]", "documentation": "EBP 002 [Member]" } } }, "auth_ref": [] }, "AZN_EBPAZCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPAZCommonStockMember", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "AZ Common Stock [Member]", "documentation": "AZ Common Stock [Member]" } } }, "auth_ref": [] }, "AZN_EBPCollectiveTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPCollectiveTrustMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Collective Trust [Member]", "documentation": "Collective Trust [Member]" } } }, "auth_ref": [] }, "AZN_EBPCommingledFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPCommingledFundsMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Commingled Funds [Member]", "documentation": "Commingled Funds [Member]" } } }, "auth_ref": [] }, "AZN_EBPCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPCommonStockMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Common Stock [Member]" } } }, "auth_ref": [] }, "AZN_EBPDefinedContributionPlanEmployerMatchingContributionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPDefinedContributionPlanEmployerMatchingContributionPercentage", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Eligible compensation participant contribution" } } }, "auth_ref": [] }, "AZN_EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheFour": { "xbrltype": "percentItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheFour", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions" ], "lang": { "en-us": { "role": { "label": "Basic contributions, 80 or more points" } } }, "auth_ref": [] }, "AZN_EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheOne": { "xbrltype": "percentItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheOne", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions" ], "lang": { "en-us": { "role": { "label": "Basic contributions, less than 40 points" } } }, "auth_ref": [] }, "AZN_EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheThree": { "xbrltype": "percentItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheThree", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions" ], "lang": { "en-us": { "role": { "label": "Basic contributions, 60 to 79 point" } } }, "auth_ref": [] }, "AZN_EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheTwo": { "xbrltype": "percentItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPEmployerContributionParticipantCompensationMatchedPercentageTrancheTwo", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions" ], "lang": { "en-us": { "role": { "label": "Basic contributions, 40 to 59 points" } } }, "auth_ref": [] }, "AZN_EBPInvestmentNumberOfSharesPurchasedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPInvestmentNumberOfSharesPurchasedValue", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchases" } } }, "auth_ref": [] }, "AZN_EBPPlanAssetsTransferredInTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://astrazeneca.com/20251231", "localname": "EBPPlanAssetsTransferredInTextBlock", "presentation": [ "http://astrazeneca.com/role/PlanAssetsTransferred" ], "lang": { "en-us": { "role": { "label": "Plan Assets Transferred" } } }, "auth_ref": [] }, "us-gaap-ebp_EbpRiskAndUncertaintyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EbpRiskAndUncertaintyAbstract", "auth_ref": [] }, "us-gaap-ebp_EbpRiskAndUncertaintyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EbpRiskAndUncertaintyLineItems", "presentation": [ "http://astrazeneca.com/role/RisksAndUncertainties" ], "lang": { "en-us": { "role": { "label": "EBP, Risk and Uncertainty [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r195" ] }, "us-gaap-ebp_EbpRiskAndUncertaintyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EbpRiskAndUncertaintyTable", "presentation": [ "http://astrazeneca.com/role/RisksAndUncertainties" ], "lang": { "en-us": { "role": { "label": "EBP, Risk and Uncertainty [Table]", "documentation": "Disclosure of information about risk and uncertainty of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, concentration risk." } } }, "auth_ref": [ "r195" ] }, "us-gaap-ebp_EbpSubsequentEventAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EbpSubsequentEventAbstract", "auth_ref": [] }, "us-gaap-ebp_EbpSubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EbpSubsequentEventLineItems", "presentation": [ "http://astrazeneca.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "EBP, Subsequent Event [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r52", "r163" ] }, "us-gaap-ebp_EbpSubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EbpSubsequentEventTable", "presentation": [ "http://astrazeneca.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "EBP, Subsequent Event [Table]", "documentation": "Disclosure of information about subsequent event for employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r52", "r163" ] }, "us-gaap-ebp_EmployeeBenefitPlanAccountingPolicyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAccountingPolicyAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanAccountingPolicyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAccountingPolicyLineItems", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPolicies", "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "EBP, Accounting Policy [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r201", "r206" ] }, "us-gaap-ebp_EmployeeBenefitPlanAccountingPolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAccountingPolicyTable", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPolicies", "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "EBP, Accounting Policy [Table]", "documentation": "Disclosure of information about accounting policy for employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r201", "r206" ] }, "us-gaap-ebp_EmployeeBenefitPlanAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAssetAbstract", "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanAssetHeldForInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAssetHeldForInvestment", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount of total assets in schedule of asset held for investment of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, current value of investment, participant loan, and plan interest in master trust." } } }, "auth_ref": [ "r168", "r171" ] }, "us-gaap-ebp_EmployeeBenefitPlanAssetHeldForInvestmentInvestmentExcludingPlanInterestInMasterTrustCurrentValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAssetHeldForInvestmentInvestmentExcludingPlanInterestInMasterTrustCurrentValue", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Current Value, gross", "documentation": "Current value of investment, excluding plan interest in master trust, in schedule of asset held for investment of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, derivative, investment measured at net asset value per share as practical expedient, and insurance contract." } } }, "auth_ref": [ "r93", "r176" ] }, "us-gaap-ebp_EmployeeBenefitPlanAssetHeldForInvestmentParticipantLoanAfterDeemedDistribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanAssetHeldForInvestmentParticipantLoanAfterDeemedDistribution", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Notes receivable from participants", "label": "EBP, Asset Held for Investment, Participant Loan, after Deemed Distribution", "documentation": "Amount, after deemed distribution, of participant loan in schedule of asset held for investment of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r93", "r176" ] }, "us-gaap-ebp_EmployeeBenefitPlanBasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanBasisOfAccountingPolicyTextBlock", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting", "documentation": "Disclosure of accounting policy for basis of accounting used to prepare financial statements of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r201", "r206" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecrease", "crdr": "credit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecrease", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Total deductions", "label": "EBP, Change in Net Asset Available for Benefit, Decrease", "documentation": "Amount of decrease in net asset available for benefit to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140", "r169" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecreaseAbstract", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Deductions:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecreaseForAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecreaseForAdministrativeExpense", "crdr": "credit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecrease", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Administrative expenses", "documentation": "Amount of decrease in net asset available for benefit from administrative expense incurred by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r59", "r95", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecreaseForPaymentToParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecreaseForPaymentToParticipant", "crdr": "credit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitDecrease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Benefits paid to participants", "documentation": "Amount of decrease in net asset available for benefit from payment of benefit to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), including, but not limited to, withdrawal." } } }, "auth_ref": [ "r58", "r89", "r95", "r104", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncrease", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecrease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Total additions", "label": "EBP, Change in Net Asset Available for Benefit, Increase", "documentation": "Amount of increase in net asset available for benefit to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140", "r169" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseAbstract", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Additions:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecrease", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase", "label": "EBP, Change in Net Asset Available for Benefit, Increase (Decrease)", "documentation": "Amount of increase (decrease) in net asset available for benefit to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r0", "r95", "r140", "r209" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForGainLossOnInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForGainLossOnInvestment", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForIncomeLossOnInvestment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative", "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Net appreciation (depreciation) in fair value of investments", "verboseLabel": "Total realized and unrealized gain/(loss)", "documentation": "Amount of increase (decrease) in net asset available for benefit from realized and unrealized gain (loss) on investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r15", "r56", "r109", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForIncomeLossOnInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForIncomeLossOnInvestment", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncrease", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Total investment income (loss)", "label": "EBP, Change in Net Asset Available for Benefit, Increase (Decrease) from Income (Loss) on Investment", "documentation": "Amount of increase (decrease) in net asset available for benefit from income (loss) on investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForIncomeLossOnInvestmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForIncomeLossOnInvestmentAbstract", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Investment income:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForAllocatedSharesForEsop": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForAllocatedSharesForEsop", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation" ], "lang": { "en-us": { "role": { "label": "Net increase in net assets available for benefits per financial statements", "documentation": "Amount of increase in net asset available for benefit from shares allocated for employee stock ownership plan (ESOP) or feature within employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r201" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContribution", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncrease", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Total contributions", "label": "EBP, Change in Net Asset Available for Benefit, Increase from Contribution", "documentation": "Amount of increase in net asset available for benefit from contribution to employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140", "r169" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContributionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContributionAbstract", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Contributions:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForDividendIncomeOnInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForDividendIncomeOnInvestment", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total dividend income received", "documentation": "Amount of increase in net asset available for benefit from dividend income on investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r82", "r140", "r197", "r213" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForEmployerContributionCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForEmployerContributionCash", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContribution", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Employee", "documentation": "Amount of increase in net asset available for benefit from cash contribution from employer of participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r57", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForInterestAndDividendIncomeOnInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForInterestAndDividendIncomeOnInvestment", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseDecreaseForIncomeLossOnInvestment", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Interest and dividends", "documentation": "Amount of increase in net asset available for benefit from interest and dividend income on investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r110" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForInterestIncomeOnNoteReceivableFromParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForInterestIncomeOnNoteReceivableFromParticipant", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncrease", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Interest income on notes receivable from participants", "documentation": "Amount of increase in net asset available for benefit from interest income on note receivable from participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140", "r169" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForParticipantContributionExcludingRollover": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForParticipantContributionExcludingRollover", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContribution", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Rollovers", "documentation": "Amount, excluding rollover, of increase in net asset available for benefit from contribution by participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140", "r164", "r165", "r166", "r203", "r204" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForParticipantContributionRollover": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForParticipantContributionRollover", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitIncreaseForContribution", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Employer", "documentation": "Amount of increase in net asset available for benefit from contribution transferred from another qualified plan or from individual retirement account of participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Excludes contribution for participant transmitted by employer of participant in EBP." } } }, "auth_ref": [ "r140", "r164", "r165", "r166", "r203", "r204" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitTransferToFromExternalPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitTransferToFromExternalPlan", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative", "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Plan assets transferred (Note 11)", "verboseLabel": "Total trasferred amount", "documentation": "Amount of net asset available for benefit transferred to (from) employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) from (to) external plan." } } }, "auth_ref": [ "r60", "r140", "r169", "r198" ] }, "us-gaap-ebp_EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitTransferToFromFundWithinEsop": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanChangeInNetAssetAvailableForBenefitTransferToFromFundWithinEsop", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan transferred amount", "documentation": "Amount of net asset available for benefit transferred to (from) fund within employee stock ownership plan (ESOP) or feature within employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) for debt service." } } }, "auth_ref": [ "r201" ] }, "us-gaap-ebp_EmployeeBenefitPlanContributionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanContributionTableTextBlock", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanTables" ], "lang": { "en-us": { "role": { "label": "Schedule of contribution", "documentation": "Tabular disclosure for contribution to employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r88" ] }, "us-gaap-ebp_EmployeeBenefitPlanDescriptionOfPlanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanDescriptionOfPlanAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanDescriptionOfPlanAmendmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanDescriptionOfPlanAmendmentTextBlock", "presentation": [ "http://astrazeneca.com/role/PlanAmendments" ], "lang": { "en-us": { "role": { "label": "Plan Amendments", "documentation": "The entire disclosure for description of amendment to employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r62" ] }, "us-gaap-ebp_EmployeeBenefitPlanDescriptionOfPlanLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanDescriptionOfPlanLineItems", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlan", "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions", "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/DescriptionOfPlanTables", "http://astrazeneca.com/role/PlanAmendments", "http://astrazeneca.com/role/PlanTermination" ], "lang": { "en-us": { "role": { "label": "EBP, Description of Plan [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r167" ] }, "us-gaap-ebp_EmployeeBenefitPlanDescriptionOfPlanTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanDescriptionOfPlanTable", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlan", "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions", "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/DescriptionOfPlanTables", "http://astrazeneca.com/role/PlanAmendments", "http://astrazeneca.com/role/PlanTermination" ], "lang": { "en-us": { "role": { "label": "EBP, Description of Plan [Table]", "documentation": "Disclosure of information about description of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r167" ] }, "us-gaap-ebp_EmployeeBenefitPlanDescriptionOfPlanTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanDescriptionOfPlanTextBlock", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlan" ], "lang": { "en-us": { "role": { "label": "Description of Plan", "documentation": "The entire disclosure for description of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, vesting and allocation provisions and disposition of forfeiture." } } }, "auth_ref": [ "r2", "r3", "r4", "r61", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanEmployerContributionReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanEmployerContributionReceivable", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanReceivable", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Employer contributions", "documentation": "Amount of contribution receivable from employer of participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r94", "r96", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanForfeitedNonvestedAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanForfeitedNonvestedAccount", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Forfeited nonvested account balance", "documentation": "Amount of plan asset, in forfeited nonvested account, no longer allocated to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r65", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanForfeitedNonvestedAccountDecreaseForEmployerContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanForfeitedNonvestedAccountDecreaseForEmployerContribution", "crdr": "credit", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employer contributions reduction from forfeited accounts", "documentation": "Amount of decrease in forfeited nonvested account of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) from employer contribution." } } }, "auth_ref": [ "r65", "r90", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetAssetAvailableForBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanForm5500CaptionNetAssetAvailableForBenefit", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets available for benefits per the Form 5500", "label": "EBP, Form 5500 Caption, Net Assets", "documentation": "Amount of net asset available for benefit as reported in Form 5500 caption for employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r140", "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanForm5500CaptionNetIncomeLoss", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation" ], "lang": { "en-us": { "role": { "totalLabel": "Net income per Form 5500", "label": "EBP, Form 5500 Caption, Net Income (Loss)", "documentation": "Amount of increase (decrease) in net asset available for benefit from net income (loss) as reported in Form 5500 caption for employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r170", "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractLineItems", "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables" ], "lang": { "en-us": { "role": { "label": "EBP, Fully Benefit-Responsive Investment Contract [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r99", "r108" ] }, "us-gaap-ebp_EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTable", "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables" ], "lang": { "en-us": { "role": { "label": "EBP, Fully Benefit-Responsive Investment Contract [Table]", "documentation": "Disclosure of information about fully benefit-responsive investment contract held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r99", "r108", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTableTextBlock", "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of investment contract values", "documentation": "Tabular disclosure of fully benefit-responsive investment contract held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r211" ] }, "us-gaap-ebp_EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanFullyBenefitResponsiveInvestmentContractTextBlock", "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts" ], "lang": { "en-us": { "role": { "label": "Fully Benefit-Responsive Investment Contracts", "documentation": "The entire disclosure for fully benefit-responsive investment contract held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r105", "r106", "r107", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentAcquiredExcludingPlanInterestInMasterTrustCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentAcquiredExcludingPlanInterestInMasterTrustCost", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of investment", "documentation": "Cost of investment, excluding plan interest in master trust, acquired by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r181", "r187", "r192" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustContractValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustContractValue", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairAndContractValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Investments in fully benefit-responsive investment contracts, at contract value", "verboseLabel": "Total", "documentation": "Contract value of investment, excluding plan interest in master trust, held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, insurance contract meeting fully benefit-responsive investment criteria." } } }, "auth_ref": [ "r69", "r75", "r108", "r140", "r205" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairAndContractValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairAndContractValue", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanNetAssetAvailableForBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Total investments", "label": "EBP, Investment, Excluding Plan Interest in Master Trust, Fair and Contract Value", "documentation": "Fair and contract value of investment, excluding plan interest in master trust, held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, derivative, investment measured at net asset value per share as practical expedient, and insurance contract." } } }, "auth_ref": [ "r202" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairValue", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanInvestmentExcludingPlanInterestInMasterTrustFairAndContractValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails", "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Investments at fair value", "verboseLabel": "Total investments at fair value", "terseLabel": "Current Value", "documentation": "Fair value of investment, excluding plan interest in master trust, held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, derivative, investment measured at net asset value per share as practical expedient, and insurance contract not meeting fully-benefit responsive investment criteria." } } }, "auth_ref": [ "r14", "r16", "r17", "r24", "r25", "r27", "r28", "r34", "r35", "r37", "r99", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentFairValueAbstract", "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Investments:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentFairValueAndNavAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentFairValueAndNavAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentFairValueAndNavLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentFairValueAndNavLineItems", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurements", "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "EBP, Investment, Fair Value and NAV [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r29", "r30", "r31", "r34", "r35", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r66", "r86", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentFairValueAndNavTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentFairValueAndNavTable", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurements", "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "EBP, Investment, Fair Value and NAV [Table]", "documentation": "Disclosure of information about fair value of investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), including, but not limited to, fair value measured at net asset value per share as practical expedient (NAV)." } } }, "auth_ref": [ "r28", "r29", "r30", "r31", "r34", "r35", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r66", "r86", "r102", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentFairValueAndNavTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentFairValueAndNavTableTextBlock", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of fair values of investments", "documentation": "Tabular disclosure of fair value of investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), including, but not limited to, fair value measured at net asset value per share as practical expedient (NAV)." } } }, "auth_ref": [ "r26", "r33", "r35", "r36", "r44", "r140", "r207", "r208", "r212" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentFairValueAndNavTextBlock", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "The entire disclosure for fair value of investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), including, but not limited to, fair value measured at net asset value per share as practical expedient (NAV)." } } }, "auth_ref": [ "r29", "r31", "r32", "r34", "r35", "r37", "r40", "r41", "r42", "r43", "r66", "r86", "r87", "r99", "r100", "r140", "r162" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentNumberOfShares", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Investment, number of shares", "documentation": "Number of shares or units of investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r67", "r93", "r174", "r178", "r181", "r182", "r184" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentPlanInterestInMasterTrustFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentPlanInterestInMasterTrustFairValue", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Total assets in the fair value hierarchy", "documentation": "Fair value of plan interest in master trust held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r54", "r75", "r141", "r205" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentPolicyTextBlock", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment Valuation and Income Recognition", "documentation": "Disclosure of accounting policy for investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r98", "r102", "r103", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanInvestmentSoldExcludingPlanInterestInMasterTrustSellingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanInvestmentSoldExcludingPlanInterestInMasterTrustSellingPrice", "crdr": "credit", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock", "documentation": "Amount of selling price for investment, excluding plan interest in master trust, sold by employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r86", "r180", "r181", "r185", "r193" ] }, "us-gaap-ebp_EmployeeBenefitPlanNetAssetAvailableForBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNetAssetAvailableForBenefit", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetAssetAvailableForBenefit", "weight": 1.0, "order": 1.0 }, "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets available for benefits", "periodStartLabel": "Beginning of the year", "periodEndLabel": "End of the year", "label": "Net assets available for benefits per the financial statements", "documentation": "Amount of asset less liability available to pay benefit of participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), including, but not limited to, aggregation of participants' individual account balances." } } }, "auth_ref": [ "r1", "r55", "r80", "r91", "r92", "r101", "r113", "r140", "r141", "r205" ] }, "us-gaap-ebp_EmployeeBenefitPlanNetAssetAvailableForBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNetAssetAvailableForBenefitAbstract", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Net assets available for benefits:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanNoteReceivableFromParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNoteReceivableFromParticipant", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanReceivable", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Notes receivable from participants", "documentation": "Amount of unpaid principal plus accrued but unpaid interest for loan from participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r97", "r140", "r205" ] }, "us-gaap-ebp_EmployeeBenefitPlanNoteReceivableFromParticipantAccountMaximumBorrowingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNoteReceivableFromParticipantAccountMaximumBorrowingAmount", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum loan account balance", "documentation": "Amount of maximum account balance that participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) can borrow." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanNoteReceivableFromParticipantAccountMaximumBorrowingToTotalAccountPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNoteReceivableFromParticipantAccountMaximumBorrowingToTotalAccountPercentage", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum account balance", "documentation": "Percentage of maximum account balance that participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) can borrow to total participant account balance." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanNoteReceivableFromParticipantAccountMinimumBorrowingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNoteReceivableFromParticipantAccountMinimumBorrowingAmount", "crdr": "debit", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum loan amount", "documentation": "Amount of minimum account balance that participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) can borrow." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanNoteReceivableFromParticipantPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanNoteReceivableFromParticipantPolicyTextBlock", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Notes Receivable from Participants", "documentation": "Disclosure of accounting policy for note receivable from participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanParticipantContributionPretaxMaximumAnnualCompensationToTotalCompensationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanParticipantContributionPretaxMaximumAnnualCompensationToTotalCompensationPercentage", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum annual compensation", "documentation": "Percentage of maximum pretax annual compensation that participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), is permitted to contribute to total pretax annual compensation." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanParticipantContributionReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanParticipantContributionReceivable", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanReceivable", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Employee contributions", "documentation": "Amount of contribution receivable from participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r94", "r96", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanParticipantLoanInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanParticipantLoanInterestRate", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Participant loan, interest rate", "verboseLabel": "Interest rate", "documentation": "Interest rate on participant loan in schedule of asset held for investment of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r93", "r176" ] }, "us-gaap-ebp_EmployeeBenefitPlanPaymentToParticipantPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanPaymentToParticipantPolicyTextBlock", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Payment of Benefits", "documentation": "Disclosure of accounting policy for payment of benefit to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanPlanTerminationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanPlanTerminationTextBlock", "presentation": [ "http://astrazeneca.com/role/PlanTermination" ], "lang": { "en-us": { "role": { "label": "Plan Termination", "documentation": "The entire disclosure for terminating employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), including, but not limited to, plan under which participant no longer accrues benefit but remains in existence to pay already accrued benefit." } } }, "auth_ref": [ "r114", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReceivable", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanNetAssetAvailableForBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "totalLabel": "Total receivables", "label": "EBP, Receivable", "documentation": "Amount of receivable of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r140", "r205" ] }, "us-gaap-ebp_EmployeeBenefitPlanReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReceivableAbstract", "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "Receivables:" } } }, "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500Abstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500Abstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500ChangeInNetAssetAvailableForBenefitDecreaseForDeemedDistributionCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500ChangeInNetAssetAvailableForBenefitDecreaseForDeemedDistributionCurrentPeriod", "crdr": "credit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation" ], "lang": { "en-us": { "role": { "negatedLabel": "Adjustment from contract value to fair value for fully-benefit responsive investment contracts held by the Stable Value Fund as of December 31, 2025", "label": "EBP, Reconciliation to Form 5500, Change in Net Asset Available for Benefit, Current Period, Decrease from Deemed Distribution", "documentation": "Amount of decrease in net asset available for benefit from deemed distribution in current period to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) to reconcile change in net asset available for benefit per financial statement to Form 5500 caption. Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r170", "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500ChangeInNetAssetAvailableForBenefitIncreaseForDeemedDistributionPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500ChangeInNetAssetAvailableForBenefitIncreaseForDeemedDistributionPriorPeriod", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation" ], "lang": { "en-us": { "role": { "label": "Adjustment from contract value to fair value for fully-benefit responsive investment contracts held by the Stable Value Fund as of December 31, 2024", "documentation": "Amount of increase in net asset available for benefit from deemed distribution in prior period to participant in employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) to reconcile change in net asset available for benefit per financial statement to Form 5500 caption. Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r170", "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500LineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500LineItems", "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables" ], "lang": { "en-us": { "role": { "label": "EBP, Reconciliation of Financial Statement to Form 5500 [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500NetAssetAvailableForBenefitContractValueToCurrentValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500NetAssetAvailableForBenefitContractValueToCurrentValueAdjustment", "crdr": "debit", "calculation": { "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation": { "parentTag": "us-gaap-ebp_EmployeeBenefitPlanForm5500CaptionNetAssetAvailableForBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation" ], "lang": { "en-us": { "role": { "label": "Adjustment from contract value to fair value for fully-benefit responsive investment contracts held by the Stable Value Fund", "documentation": "Amount of current value in excess of (less than) contract value of investment held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) to reconcile net asset available for benefit per financial statement to Form 5500 caption. Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r170", "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500Table": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500Table", "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables" ], "lang": { "en-us": { "role": { "label": "EBP, Reconciliation of Financial Statement to Form 5500 [Table]", "documentation": "Disclosure of information about reconciliation of financial statement to Form 5500 for employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r200" ] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500TableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500TableTextBlock", "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables" ], "lang": { "en-us": { "role": { "label": "EBP, Reconciliation of Financial Statement to Form 5500 [Table Text Block]", "documentation": "Tabular disclosure of reconciliation of financial statement to Form 5500 for employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanReconciliationToForm5500TextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanReconciliationToForm5500TextBlock", "presentation": [ "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Financial Statements to Form 5500", "documentation": "The entire disclosure for reconciliation of financial statement to Form 5500 for employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Form 5500 is form provided by Department of the Treasury, Internal Revenue Service (IRS); Department of Labor (DOL), Employee Benefit Security Administration (EBSA); and Pension Benefit Guaranty Corporation (PBGC)." } } }, "auth_ref": [ "r64", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsLineItems", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactions", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "EBP, Related Party and Party-in-Interest Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r50", "r201", "r206" ] }, "us-gaap-ebp_EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTable", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactions", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "EBP, Related Party and Party-in-Interest Transactions [Table]", "documentation": "Disclosure of information about related party and party-in-interest transactions with employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r50", "r201", "r206" ] }, "us-gaap-ebp_EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanRelatedPartyAndPartyInInterestTransactionsTextBlock", "presentation": [ "http://astrazeneca.com/role/Party-in-interestTransactions" ], "lang": { "en-us": { "role": { "label": "Party-in-Interest Transactions", "documentation": "The entire disclosure for related party and party-in-interest transactions with employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r47", "r48", "r49", "r50", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanRiskAndUncertaintyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanRiskAndUncertaintyTextBlock", "presentation": [ "http://astrazeneca.com/role/RisksAndUncertainties" ], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties", "documentation": "The entire disclosure for risk and uncertainty of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, concentration risk." } } }, "auth_ref": [ "r7", "r11", "r13", "r45", "r46", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentLineItems", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "EBP, Schedule of Asset Held for Investment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r93", "r173", "r174", "r175", "r176" ] }, "us-gaap-ebp_EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTable", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "EBP, Schedule of Asset Held for Investment [Table]", "documentation": "Disclosure of information about schedule of asset held for investment of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r93", "r173", "r174", "r175", "r176" ] }, "us-gaap-ebp_EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanScheduleOfAssetHeldForInvestmentTableTextBlock", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets (Held at End of Year)", "documentation": "Tabular disclosure of schedule of asset held for investment of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r168", "r172" ] }, "us-gaap-ebp_EmployeeBenefitPlanStatementOfChangeInNetAssetAvailableForBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanStatementOfChangeInNetAssetAvailableForBenefitAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanStatementOfChangeInNetAssetAvailableForBenefitLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanStatementOfChangeInNetAssetAvailableForBenefitLineItems", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "EBP, Statement of Change in Net Asset Available for Benefit [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r83", "r84", "r85", "r101" ] }, "us-gaap-ebp_EmployeeBenefitPlanStatementOfChangeInNetAssetAvailableForBenefitTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanStatementOfChangeInNetAssetAvailableForBenefitTable", "presentation": [ "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "EBP, Statement of Change in Net Asset Available for Benefit [Table]", "documentation": "Presentation of information about change in net asset available for benefit for employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r83", "r84", "r85", "r101" ] }, "us-gaap-ebp_EmployeeBenefitPlanStatementOfNetAssetAvailableForBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanStatementOfNetAssetAvailableForBenefitAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanStatementOfNetAssetAvailableForBenefitLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanStatementOfNetAssetAvailableForBenefitLineItems", "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "EBP, Statement of Net Asset Available for Benefit [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r99", "r101", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125" ] }, "us-gaap-ebp_EmployeeBenefitPlanStatementOfNetAssetAvailableForBenefitTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanStatementOfNetAssetAvailableForBenefitTable", "presentation": [ "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits" ], "lang": { "en-us": { "role": { "label": "EBP, Statement of Net Asset Available for Benefit [Table]", "documentation": "Presentation of information about net asset available for benefit for employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r99", "r101", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124" ] }, "us-gaap-ebp_EmployeeBenefitPlanSubsequentEventTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanSubsequentEventTextBlock", "presentation": [ "http://astrazeneca.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for subsequent event in financial statement of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r51", "r53", "r201", "r206" ] }, "us-gaap-ebp_EmployeeBenefitPlanSummaryOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanSummaryOfAccountingPolicyTextBlock", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies", "documentation": "The entire disclosure for summary of accounting policy used to prepare financial statement of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r2", "r3", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanSyntheticInvestmentContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanSyntheticInvestmentContractMember", "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts" ], "lang": { "en-us": { "role": { "label": "EBP, Synthetic Investment Contract [Member]", "documentation": "Contract, held by employee stock purchase, saving, or similar plan (employee benefit plan (EBP)), simulating performance of traditional guaranteed investment contract through use of financial instrument." } } }, "auth_ref": [ "r127", "r128", "r129", "r139", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanTaxStatusAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanTaxStatusAbstract", "auth_ref": [] }, "us-gaap-ebp_EmployeeBenefitPlanTaxStatusLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanTaxStatusLineItems", "presentation": [ "http://astrazeneca.com/role/InternalRevenueServiceStatus" ], "lang": { "en-us": { "role": { "label": "EBP, Tax Status [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r199" ] }, "us-gaap-ebp_EmployeeBenefitPlanTaxStatusTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanTaxStatusTable", "presentation": [ "http://astrazeneca.com/role/InternalRevenueServiceStatus" ], "lang": { "en-us": { "role": { "label": "EBP, Tax Status [Table]", "documentation": "Disclosure of information about tax status of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, information concerning whether tax ruling or determination letter was obtained and principal assumption on which plan relied in not making provision for federal income tax." } } }, "auth_ref": [ "r199" ] }, "us-gaap-ebp_EmployeeBenefitPlanTaxStatusTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanTaxStatusTextBlock", "presentation": [ "http://astrazeneca.com/role/InternalRevenueServiceStatus" ], "lang": { "en-us": { "role": { "label": "Internal Revenue Service Status", "documentation": "The entire disclosure for tax status of employee stock purchase, saving, or similar plan (employee benefit plan (EBP)). Includes, but is not limited to, information concerning whether tax ruling or determination letter was obtained and principal assumption on which plan relied in not making provision for federal income tax." } } }, "auth_ref": [ "r63", "r68", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanTraditionalGuaranteedInvestmentContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanTraditionalGuaranteedInvestmentContractMember", "presentation": [ "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts" ], "lang": { "en-us": { "role": { "label": "EBP, Traditional Guaranteed Investment Contract [Member]", "documentation": "Contract between insurance entity and employee stock purchase, saving, or similar plan (employee benefit plan (EBP)) providing guaranteed return on principal invested over specified period of time." } } }, "auth_ref": [ "r127", "r128", "r129", "r139", "r140" ] }, "us-gaap-ebp_EmployeeBenefitPlanUseOfEstimatePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap-ebp/2025", "localname": "EmployeeBenefitPlanUseOfEstimatePolicyTextBlock", "presentation": [ "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for use of estimate in preparation of financial statement of employee stock purchase, saving, or similar plan (employee benefit plan (EBP))." } } }, "auth_ref": [ "r5", "r6", "r8", "r9", "r10", "r12", "r140" ] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitiesTable", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r148" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r144" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://astrazeneca.com/role/Cover", "http://astrazeneca.com/role/DescriptionOfPlan", "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions", "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/DescriptionOfPlanTables", "http://astrazeneca.com/role/FairValueMeasurements", "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FairValueMeasurementsTables", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables", "http://astrazeneca.com/role/InternalRevenueServiceStatus", "http://astrazeneca.com/role/Party-in-interestTransactions", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative", "http://astrazeneca.com/role/PlanAmendments", "http://astrazeneca.com/role/PlanAssetsTransferred", "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative", "http://astrazeneca.com/role/PlanTermination", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables", "http://astrazeneca.com/role/RisksAndUncertainties", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails", "http://astrazeneca.com/role/SignificantAccountingPolicies", "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies", "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r144" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r161" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r144" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInformationLineItems", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r158" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r156" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r144" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r144" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r144" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r144" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r159" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "auth_ref": [ "r28", "r29", "r30", "r31", "r34", "r35", "r37", "r100", "r140" ] }, "us-gaap_FairValueInputsLevel12And3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel12And3Member", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]" } } }, "auth_ref": [ "r196", "r208", "r210" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "auth_ref": [ "r28", "r34", "r126", "r140" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "auth_ref": [ "r28", "r29", "r34", "r126", "r140" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "auth_ref": [ "r28", "r29", "r30", "r31", "r34", "r35", "r126", "r140" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "auth_ref": [ "r28", "r29", "r30", "r31", "r34", "r35", "r37", "r100", "r140" ] }, "us-gaap_InvestmentIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentIdentifierAxis", "presentation": [ "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Identifier [Axis]" } } }, "auth_ref": [ "r93", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentTypeAxis", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]" } } }, "auth_ref": [ "r14", "r15", "r16", "r17", "r18", "r19", "r20", "r21", "r22", "r23", "r24", "r27", "r28", "r29", "r30", "r31", "r34", "r35", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r66", "r70", "r71", "r72", "r73", "r74", "r75", "r81", "r83", "r84", "r85", "r86", "r93", "r99", "r108", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r140", "r141", "r176", "r195", "r205" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative" ], "auth_ref": [ "r14", "r15", "r16", "r17", "r18", "r19", "r20", "r21", "r22", "r23", "r24", "r27", "r28", "r29", "r30", "r31", "r34", "r35", "r37", "r38", "r39", "r40", "r41", "r42", "r43", "r66", "r70", "r71", "r72", "r73", "r74", "r75", "r81", "r83", "r84", "r85", "r86", "r93", "r99", "r108", "r111", "r112", "r115", "r116", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r140", "r141", "r176", "r195", "r205" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://astrazeneca.com/role/Cover", "http://astrazeneca.com/role/DescriptionOfPlan", "http://astrazeneca.com/role/DescriptionOfPlanDetails-Contributions", "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/DescriptionOfPlanTables", "http://astrazeneca.com/role/FairValueMeasurements", "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment", "http://astrazeneca.com/role/FairValueMeasurementsTables", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsDetails-InvestmentContracts", "http://astrazeneca.com/role/FullyBenefit-responsiveInvestmentContractsTables", "http://astrazeneca.com/role/InternalRevenueServiceStatus", "http://astrazeneca.com/role/Party-in-interestTransactions", "http://astrazeneca.com/role/Party-in-interestTransactionsDetailsNarrative", "http://astrazeneca.com/role/PlanAmendments", "http://astrazeneca.com/role/PlanAssetsTransferred", "http://astrazeneca.com/role/PlanAssetsTransferredDetailsNarrative", "http://astrazeneca.com/role/PlanTermination", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Details-Reconciliation", "http://astrazeneca.com/role/ReconciliationOfFinancialStatementsToForm5500Tables", "http://astrazeneca.com/role/RisksAndUncertainties", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYear", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails", "http://astrazeneca.com/role/SignificantAccountingPolicies", "http://astrazeneca.com/role/SignificantAccountingPoliciesPolicies", "http://astrazeneca.com/role/StatementOfChangesInNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/StatementsOfNetAssetsAvailableForBenefits", "http://astrazeneca.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r31", "r140", "r168", "r176" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r31", "r140", "r168", "r176" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MoneyMarketFundsMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]" } } }, "auth_ref": [ "r168", "r207", "r210", "r214" ] }, "us-gaap_MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MutualFundMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Mutual Fund [Member]" } } }, "auth_ref": [ "r116", "r127", "r130", "r139", "r140", "r141" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r155" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r149" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r151" ] }, "us-gaap_PrivateEquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrivateEquityFundsMember", "presentation": [ "http://astrazeneca.com/role/FairValueMeasurementsDetails-FairValuesOfInvestment" ], "lang": { "en-us": { "role": { "label": "Private Equity Funds [Member]" } } }, "auth_ref": [ "r168", "r207", "r210", "r214" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r31", "r140", "r168", "r176" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://astrazeneca.com/role/DescriptionOfPlanDetailsNarrative", "http://astrazeneca.com/role/ScheduleOfAssetsHeldAtEndOfYearDetails" ], "auth_ref": [ "r31", "r140", "r168", "r176" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r143" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r147" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r146" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r152" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r150" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://astrazeneca.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r160" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SAB Topic 11.M)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-8" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-10" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-2" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-7" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-7" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-7" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-7" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-8" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-02(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-02(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-02(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-02(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(2)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(2)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(2)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(2)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(2)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(5)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule II))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule III))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478642/962-310-45-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478642/962-310-45-2" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478844/962-325-35-1B" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-6" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-8" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-2A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-2B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8B" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479750/962-40-25-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "962", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479684/962-40-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4L", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4L" }, "r116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-6" }, "r127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" }, "r139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8B" }, "r140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478873/962-325-55-17" }, "r141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478873/962-325-55-18" }, "r142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r162": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule III))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-2B" }, "r167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "205", "Topic": "962", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule I))", "SubTopic": "205", "Topic": "962", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule III))", "SubTopic": "205", "Topic": "962", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "1", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "DOL-EBSA" }, "r171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "DOL-EBSA" }, "r172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(1)(i)", "Publisher": "DOL-EBSA" }, "r173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(1)(i)(A)", "Publisher": "DOL-EBSA" }, "r174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(1)(i)(B)", "Publisher": "DOL-EBSA" }, "r175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(1)(i)(C)", "Publisher": "DOL-EBSA" }, "r176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(1)(i)(D)", "Publisher": "DOL-EBSA" }, "r177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(2)(i)(A)", "Publisher": "DOL-EBSA" }, "r178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(2)(i)(B)", "Publisher": "DOL-EBSA" }, "r179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(2)(i)(C)", "Publisher": "DOL-EBSA" }, "r180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(2)(i)(D)", "Publisher": "DOL-EBSA" }, "r181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "DOL-EBSA" }, "r182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "10", "Paragraph": "b", "Subparagraph": "(4)", "Publisher": "DOL-EBSA" }, "r183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(i)", "Publisher": "DOL-EBSA" }, "r184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(ii)", "Publisher": "DOL-EBSA" }, "r185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(iii)", "Publisher": "DOL-EBSA" }, "r186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(iv)", "Publisher": "DOL-EBSA" }, "r187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(v)", "Publisher": "DOL-EBSA" }, "r188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(vi)", "Publisher": "DOL-EBSA" }, "r189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(1)(vii)", "Publisher": "DOL-EBSA" }, "r190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(2)(i)", "Publisher": "DOL-EBSA" }, "r191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(2)(ii)", "Publisher": "DOL-EBSA" }, "r192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(2)(iii)", "Publisher": "DOL-EBSA" }, "r193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(2)(iv)", "Publisher": "DOL-EBSA" }, "r194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Employee Retirement Income Security Act of 1974", "Number": "2520", "Section": "103", "Subsection": "6", "Paragraph": "d", "Subparagraph": "(2)(v)", "Publisher": "DOL-EBSA" }, "r195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477063/962-205-45-7" }, "r198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478416/962-205-50-1" }, "r201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(4)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-04(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6A-05(a)(Schedule II))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477804/962-205-S99-1" }, "r206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479143/962-235-S50-1" }, "r207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-5" }, "r208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-6" }, "r209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477509/962-325-45-8" }, "r210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-1" }, "r211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-3" }, "r213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-7" }, "r214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "962", "SubTopic": "325", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477783/962-325-50-8A" } } }